Sickle Cell Disease Forecast in 10 Major Markets 2017-2027

June 2017 | 44 pages | ID: SE2B31F9CA9EN
Black Swan Analysis limited

Abstracts

Sickle cell disease (SCD) is a term comprising clinically relevant haemoglobinopathies caused by mutations in the HBB gene resulting in sickle haemoglobin (HbS). It is the most common genetic disorder worldwide. Clinically, SCD presents a wide variety of forms that range from mild to very severe, depending on the genotype, with a broad range of comorbidities. The most common and severe form, constituting the majority of SCD cases worldwide, is caused by a homozygous inheritance of a single point mutation in the β globin subunit and is usually called “SCD SS” or “sickle cell anaemia” (SCA).

This report provides the current prevalent population for Sickle cell disease across 10 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Russia, Canada and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Sickle cell disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

These common Sickle cell disease co-morbidities include:

• Vaso-occlusive crisis
• Splenic sequestration
• Chronic anaemia
• Renal failure
• Retinopathy
• Asthma
• Stroke
• Dactylitis
• Pulmonary hypertension
• Acute chest syndrome
• Priapism

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global sickle cell disease market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of sickle cell disease and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on sickle cell disease prevalent population.
• Identify sub-populations within sickle cell disease which require treatment.
• Gain an understanding of the specific markets that have the largest number of sickle cell disease patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Comorbid conditions/features associated with the disease
Methodology for quantification of patient numbers
Top-line prevalence for sickle cell disease
Features of Sickle Cell Disease Patients
o Combinations of HBB alleles in SCD patients
Comorbid conditions of SCD patients
Abbreviations used in the report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES

Prevalence of Sickle Cell Disease, total (000s)
Prevalence of Sickle Cell Disease, males (000s)
Prevalence of Sickle Cell Disease, females (000s)
SCD Patients by Allele Combination, total (000s)
SCD Patients with Chronic Anaemia, total (000s)
SCD Patients with Vaso-occlusive Crisis, total (000s)
SCD Patients with Splenic Sequestration, total (000s)
SCD Patients with Dactylitis, total (000s)
SCD Patients with Acute Chest Syndrome, total (000s)
SCD Patients with Retinopathy, total (000s)
SCD Patients with Renal Failure, total (000s)
SCD Patients with Asthma, total (000s)
SCD Patients with Stroke, total (000s)
SCD Patients with Priapism, total (000s)
SCD Patients with Pulmonary Hypertension, total (000s)
Abbreviations and Acronyms used in the report
USA Prevalence of Sickle Cell Disease by 5-yr age cohort, male (000s)
USA Prevalence of Sickle Cell Disease by 5-yr age cohort, female (000s)
Canada Prevalence of Sickle Cell Disease by 5-yr age cohort, male (000s)
Canada Prevalence of Sickle Cell Disease by 5-yr age cohort, female (000s)
France Prevalence of Sickle Cell Disease by 5-yr age cohort, male (000s)
France Prevalence of Sickle Cell Disease by 5-yr age cohort, female (000s)
Germany Prevalence of Sickle Cell Disease by 5-yr age cohort, male (000s)
Germany Prevalence of Sickle Cell Disease by 5-yr age cohort, female (000s)
Italy Prevalence of Sickle Cell Disease by 5-yr age cohort, male (000s)
Italy Prevalence of Sickle Cell Disease by 5-yr age cohort, female (000s)
Spain Prevalence of Sickle Cell Disease by 5-yr age cohort, male (000s)
Spain Prevalence of Sickle Cell Disease by 5-yr age cohort, female (000s)
UK Prevalence of Sickle Cell Disease by 5-yr age cohort, male (000s)
UK Prevalence of Sickle Cell Disease by 5-yr age cohort, female (000s)
Russia Prevalence of Sickle Cell Disease by 5-yr age cohort, male (000s)
Russia Prevalence of Sickle Cell Disease by 5-yr age cohort, female (000s)
Brazil Prevalence of Sickle Cell Disease by 5-yr age cohort, male (000s)
Brazil Prevalence of Sickle Cell Disease by 5-yr age cohort, female (000s)
India Prevalence of Sickle Cell Disease by 5-yr age cohort, male (000s)
India Prevalence of Sickle Cell Disease by 5-yr age cohort, female (000s)